Dear Doctor - Participate in the Survey on thromboprophylaxis " A recent survey of patients with thrombophilia found that most patients are not receiving adequate thromboprophylaxis. Thrombophilia is a condition that predisposes patients to developing blood clots, and thromboprophylaxis is the use of medication or other interventions to prevent blood clots from forming.The survey found that only 43% of patients with thrombophilia were receiving anticoagulant medication, which is the most effective form of thromboprophylaxis. This means that the majority of patients with thrombophilia are not being adequately protected from developing blood clots.There are several reasons why patients with thrombophilia may not be receiving appropriate thromboprophylaxis. First, many patients are not aware that they have thrombophilia. Second, even when patients are aware of their condition, they may not be aware of the importance of using anticoagulants or other forms of thromboprophylaxis. Third, some patients may be reluctant to take anticoagulants because of the potential side effects. Finally, some physicians may not be familiar with the latest guidelines for managing thrombophilia and therefore may not be prescribing anticoagulants to their patients with this condition.The results of this survey underscore the need for better education for both patients and physicians about thrombophilia . Participate in Surveys "
1.
Imfinzi + Imjudo, EU approved for patients with advanced lung cancer and non-small cell lung cancer: AstraZeneca
2.
More Support for Early Detection; Cancer in Men Rising; Diet Drives Colon Cancer
3.
Asymptomatic Brain Metastases in EGFR-Mutant NSCLC
4.
Mapping lifelong chronic health risks for childhood cancer survivors
5.
Adding Chemo to Osimertinib Doubles PFS in Advanced NSCLC
1.
Respiratory Ramifications of Systemic Disease: A Comprehensive Review
2.
Revolutionizing Lung Cancer Treatment: Exploring the Benefits of Wedge Resection Surgery
3.
Trends in Incidence, Care, and Surgery for Medullary Thyroid Cancer: A Review
4.
Cancer Care Advances: Metformin, Digital Tools, and Artificial Renal Support
5.
Molecular Mechanisms, Clinical Efficacy, and Stem Cell Therapy Integration in Leukemia Treatment
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Treatment Paradigm for Patients with R/R Adult B-cell ALL- Expert Discussions
2.
First Line Combination Therapy- The Overall Survival Data in NSCLC Patients
3.
Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
5.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation